Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NBIXBearishResearch Analysisnews

High materiality8/10

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile

Nov 11, 2025, 1:16 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Failure to meet primary endpoints could concern investors about future drugs. Historical data shows significant price declines after similar study failures.

AI summary

What happened, with direct paths to the underlying reporting

NBIX's study for NBI-1070770 did not meet primary efficacy endpoints. The drug was generally well tolerated despite study results. Neurocrine reported adjusted earnings of $2.17 per share, exceeding estimates. Sales of $794.9 million topped Wall Street forecasts. Stock price fell 2.64% following the study announcement.

NBIX's study for NBI-1070770 did not meet primary efficacy endpoints.
The drug was generally well tolerated despite study results.
Neurocrine reported adjusted earnings of $2.17 per share, exceeding estimates.
Sales of $794.9 million topped Wall Street forecasts.
Stock price fell 2.64% following the study announcement.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile

NBIX Vykat XR safety concerns in Prader-Willi raise near-term risk

Neurocrine Acquires Soleno, Expanding Portfolio and Boosting Revenue Potential

Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage